Original Article

Prescriptions for a Toxic Combination: Use of Methotrexate Plus Trimethoprim-Sulfamethoxazole in the United States

Authors: Scott A. Davis, MA, Daniel P. Krowchuk, MD, Steven R. Feldman, MD, PhD

Abstract

Objectives: To determine the frequency of using the potentially toxic combination of methotrexate and trimethoprim-sulfamethoxazole (TMP-SMX) in outpatient practice in the United States.

Methods: Data from the National Ambulatory Medical Care Survey for 1993–2010 were used to assess the frequency of using methotrexate with TMP-SMX and associated physician specialties and diagnoses.

Results: TMP-SMX was coprescribed in 22,000 methotrexate visits per year (1.0% of methotrexate visits). Pediatricians prescribed the combination most frequently, and the most common diagnosis was acute lymphoblastic leukemia. There was no significant change over time in coprescription of TMP-SMX with methotrexate ( P = 0.4).

Conclusions: Low-dose TMP-SMX with methotrexate chemotherapy appears to be standard for patients with acute lymphoblastic leukemia; however, other uses appear questionable, and clinicians should be cognizant of the risk for fatal interactions, especially when medications are prescribed by multiple providers.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 2010; 37:1416-1421.
 
2. Yamazaki H, Nanki T, Miyasaka N, et al. Methotrexate and trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis. J Rheumatol 2011;38:777.
 
3. Agrawal AK, Chang PP, Feusner J. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011;33:e1-e4.